+ Watch CYTK
on My Watchlist
A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.
Recent baby bio optimism and a bone from Amgen have combined to puff Cytokinetics stock to an eight month high. But CK-1827452 hasn't been shown to have any clinical benefit yet as trials so far have only evaluated changes in physiologic parameters. The KSP inhibitor program appears to be in tatters, with the remnants being pushed around on the plate by Glaxo. Amgen's 50M, while insignificant for them, will keep Cytokinetics around for a few more waxes and wanes. I'm betting on the next move being a wane.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions